Anupma Nayak, MBBS, MD
Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Attending Pathologist, Hospital of the University of Pennsylvania
Director, Breast Pathology Fellowship Program, Department of Pathology and Laboratory Medicine,Perelman School of Medicine and Hospital of the University of Pennsylvania
Director, Tumor Tissue and Biobank (TTAB), Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
Department: Pathology and Laboratory Medicine
Contact information
Associate Professor
Dept. of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
Perelman School of Medicine
3400 Spruce St.
6 Founders
Philadelphia, PA 19104
Dept. of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
Perelman School of Medicine
3400 Spruce St.
6 Founders
Philadelphia, PA 19104
Office: 2156624899
Publications
Education:
MBBS (Medicine)
King George Medical College, Lucknow, India, 1997.
Permanent linkMBBS (Medicine)
King George Medical College, Lucknow, India, 1997.
Description of Clinical Expertise
Breast PathologyDescription of Research Expertise
Breast CancerSelected Publications
Tondi Resta I, Nelson ND, Toorens E, Bleiweiss IJ, Nayak A. : Mucinous Cystadenocarcinomas of the Breast Exhibit Heterogeneous Genomic Profile as Triple Negative Breast Cancer, Harbor Alterations in PIK3CA, PTEN, AKT1, and GNAS Genes, and May Not Be Indolent. Int J Surg Pathol. April 2025 Notes: Corresponding Author.Narasimhamurthy M, Le A, Boruah N, Moses R, Kelly G, Bleiweiss I, Maxwell KN, Nayak A. : Clinicopathologic Features of Breast Tumors in Germline TP53 Variant-Associated Li-Fraumeni Syndrome. Am J Surg Pathol. 49(3): 195-205, March 2025 Notes: Corresponding Author.
Kaitlin Demarest, Arravinth Anantharajah, Kara N. Maxwell1, Mersedeh Rohanizadegan, Angela Bradbury, Katherine L Nathanson, Susan Domchek, Anupma Nayak, Payal D. Shah: Pathogenic Germline Variants in Patients with Metaplastic Breast Cancer. JAMA Network Open 8(2), Feb 2025.
Young AJ, Pantel AR, Kiani M, Doot RK, Bagheri S, Pryma DA, Farwell MD, Li S, Lee H, Schubert EK, Secreto A, Zuckerman SP, Nayak A, Choi H, Carlin S, DeMichele A, Mankoff DA, Zhou R, Mach RH, McDonald ES. : Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET in Breast Cancer. J Nucl Med. 65((12)): 1862-68, Dec 2024.
Li X, Nguyen TTA, Zhang J, Nayak A, Liu Y, Duckworth LA, Zhang G, Bakkar R, Agarwal I, Hou Y, Guo H, Huang X, Wei S, Yasmeen S, Thaer K, Huang H, Zhang H, Smith GH, Turashvili G, Peng L, Liu Y, Yang W, Siziopikou KP. : Validation Study of the Newly Proposed Refined Diagnostic Criteria for Malignant Phyllodes Tumor With 136 Borderline and Malignant Phyllodes Tumor Cases. Am J Surg Pathol 48(9): 1146-1153, Sept 2024.
Tchou J, Gottipati S, Goldbach M, Baxter M, Venters S, Chen Y, Gonzalves D, Ahmad Z, Nayak A, Mukhtar R, Boughey J.: Change in Biomarker Profile after neoadjuvant chemotherapy is prognostic and is especially common in patients with HER2+ breast cancer. Annals of Surgical Oncology Aug 2024.
Boruah N, Hoyos D, Moses R, Hausler R, Desai H, Le AN, Good M, Kelly G, Raghavakaimal A, Tayeb M, Narasimhamurthy M, Doucette A, Gabriel P, Feldman MJ, Park J, de Rodas ML, Schalper KA, Goldfarb SB, Nayak A, Levine AJ, Greenbaum BD, Maxwell KN.: Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers. bioRxiv [Preprint]. Apr 2024.
Ito K, Harada I, Martinez C, Sato K, Lee E, Port E, Byerly JH, Nayak A, Tripathi E, Zhu J, Irie HY.: MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases. Cancer Res Commun. 28(4): 946-957, Mar 2024.
Wineland D, Le AN, Hausler R, Kelly G, Barrett E, Desai H, Wubbenhorst B, Pluta J, Bastian P, Symecko H, D'Andrea K, Doucette A, Gabriel P, Reiss KA, Nayak A, Feldman M, Domchek SM, Nathanson KL, Maxwell KN; Regeneron Genetics Center; Penn Medicine Biobank.: Biallelic BRCA loss and homologous recombination deficiency in non-breast/ovarian tumors in germline BRCA1/2 carriers. JCO Precision Oncology Aug 2023.
Thacker G, Henry S, Nandi A, Debnath R, Singh S, Nayak A, Susnik B, Boone MM, Zhang Q, Kesmodel SB, Gumber S, Das GM, Kambayashi T, Dos Santos CO, Chakrabarti R.: Immature natural killer cells promote progression of triple-negative breast cancer. Sci Transl Med 15(686), Mar 2023 Notes: Epub.